[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [PBNCategory](https://github.com/mm80843/T3.5/tree/main/docs/PBNCategory/index.md) >> Individual ID:PBN__PBNCategory_10 

# __Enhanced measures to inhibit the dissemination and transmission of viruses, including reducing concentration and spread.__

## Items covered in this category

* [Antiviral targets](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_167.md)
* [Better understanding of virus viability](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_360.md)
* [Decrease in virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_241.md)
* [Disinfection of aerosolized viral particles](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_274.md)
* [Enhanced antibacterial and antiviral properties](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_15.md)
* [Enhanced understanding of virus transmission mechanisms](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_674.md)
* [Estimation of virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_177.md)
* [Improved virus survival](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_95.md)
* [Inactivation of human coronaviruses](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_248.md)
* [Inactivation of respiratory animal viral aerosols](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1271.md)
* [Indication of virus circulation in the human population](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1366.md)
* [Limit virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1365.md)
* [Limited virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_64.md)
* [Microscopic representation of individual movement](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_76.md)
* [Prevent virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_77.md)
* [Prevention of viral transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1120.md)
* [Protection against virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1187.md)
* [Rapid deployment of virus-inactivating solutions](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_120.md)
* [Reduced concentration of airborne virus particles](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_615.md)
* [Reduced concentration of virus-laden microdroplets](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_268.md)
* [Reduced risk of virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_502.md)
* [Reduced virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_607.md)
* [Reduction in airborne virus concentration](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1332.md)
* [Reduction in airborne virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_237.md)
* [Reduction in virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_242.md)
* [Reduction in virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_272.md)
* [Reduction in virus viability in indoor air](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_815.md)
* [Reduction of airborne virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_371.md)
* [Reduction of airborne viruses](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_510.md)
* [Reduction of infectious viruses](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_432.md)
* [Reduction of viral titers](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_433.md)
* [Reduction of virus concentration](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_435.md)
* [Resilient transport infrastructure to prevent virus spread](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_508.md)
* [Thorough study of anti-coronavirus drugs](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_1323.md)
* [Understanding the effect of rh on uv susceptibility of pathogenic viral aerosols](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_914.md)
* [Understanding uv susceptibility of viral aerosols](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_588.md)
* [Virus recreation](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_589.md)
* [Visualizing virus transmission](https://github.com/mm80843/T3.5/blob/pages/Benef/PBN__Benef_894.md)

## Title of the category

This category of Benenefits describes various aspects related to the prevention, reduction, and understanding of virus transmission in infrastructure and the human population. It includes studies on anti-coronavirus drugs, enhanced antibacterial and antiviral properties, and rapid deployment of virus-inactivating solutions. It also covers the visualization and estimation of virus spread, indication of virus circulation in the human population, and the reduction of virus viability in indoor air. Additionally, it includes the protection against virus transmission, reduction in airborne virus concentration, and the inactivation of respiratory animal viral aerosols. Overall, this category of Benenefits focuses on the measures and mechanisms to limit, prevent, and decrease the spread of viruses in infrastructure and the wider community.

